Avenna Ltd’s Post

As this year comes to an end, we take a moment to reflect on the progress made by the DECISION consortium in 2024. Thanks to the dedication of our teams and collaborators, we’ve reached important milestones that advance our mission to improve the understanding and treatment of liver diseases. Some of the highlights of this year include: 📄 𝗞𝗲𝘆 𝗣𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻𝘀 Two important subprojects of DECISION were published this year: 🔵 Decompensated MASH-cirrhosis model by acute and toxic effects of phenobarbital: This study, a significant contribution of DECISION's Work Package 4, introduced a fast and reproducible rat model mimicking advanced MASH-cirrhosis, a crucial tool for testing new therapeutic approaches. By combining carbon tetrachloride (CCl4), a high-fat Western diet, and phenobarbital, the model captures the key features of decompensated MASH-cirrhosis seen in humans, paving the way for more effective drug development. Read the paper here: https://lnkd.in/dGs6TQS6 🔵 A robust clustering strategy for stratification unveils unique patient subgroups in acutely decompensated cirrhosis: A major output of our Work Package 3, the ClustALL pipeline was developed to address patient heterogeneity in acutely decompensated cirrhosis. This innovative clustering method identified unique patient subgroups with prognostic value and could improve clinical trial design and personalized patient management. Read the paper here: https://lnkd.in/dKZexXhE 💡 𝗣𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗖𝗢𝗠𝗕𝗔𝗧 𝗧𝗿𝗶𝗮𝗹 This year also marked the inclusion of the first patient in the COMBAT trial. This multicenter Phase II study aims to evaluate the safety, efficacy, and cost-effectiveness of a combinatorial therapy using human albumin and enoxaparin alongside standard medical care. To all our collaborators, partners, and supporters—thank you for being an integral part of DECISION’s journey. Wishing you a joyous holiday season and a successful year ahead! #DECISIONproject #LiverResearch #COMBATtrial #Hepatology #cirrhosis

🌟 Meet the minds behind SQUEEZE at the #EULAR2024 conference in June! 🌟 🔍 Meet Costantino Pitzalis, leader of our BioTest trial. The SQUEEZE prospective biomarker trial, coordinated by Queen Mary University of London is designed to check if the amount of certain markers found in the tissue affected by the disease (called “synovial tissue”, which is found in the joints) influences how well patients respond to a specific type of arthritis medication known as targeted DMARDs (Disease-modifying antirheumatic drugs). These medications are designed to act on specific parts of the disease process in #RheumatoidArthritis. By conducting this trial, we hope to understand better which patients will benefit the most from these treatments based on the levels of these markers in their joint tissue. 📍 Join us at the #SQUEEZE booth to explore groundbreaking advancements in #RA treatment. Discover the latest insights from our three trials, led by pioneering experts in #rheumatology and their teams.  #EULARCongress #PrecisionMedicine #Innovation #HealthCare #HorizonEurope #EUprojects #clinicalstudy #clinicaltrial #biotest

To all Axia Medicine's followers: our US SAFE just started! We are looking for warm introductions to US investors. Do reach out if interested. #patientsfirst #healthdata #assetmanagement #oncology #rarediseases #personalisedhealthcare #precisionmedicine #genomics #genomicmedicine #biopharma #diagnostics

Have you seen the agenda for this year's IPF Summit? Olivia has put together a fantastic program and we're excited to reunite the pulmonary fibrosis community once again this August to advance disease-modifying pulmonary fibrosis therapeutics. What's planned for this year? Access the full event guide here: https://ter.li/ipf Session spotlight: 💡 Deciphering Patient Heterogeneity Leveraging AI & Novel Models to Segment Heterogeneous Disease Populations & Unlock Personalised Medicine in IPF with Sydney Montesi, marilyn glassberg, Henrik Landgren 💡 Innovative Strategies to Mitigate the Competitive & Challenging Nature of Clinical Trials in a High-Risk, Rare Disease with Toby Maher and Jeffrey Bornstein 💡 Modelling the Repair Mechanisms to Better Understand the Regeneration Pathway & Uncover Effective Therapeutics with David Lagares 2024 Partners: FibroFind | Vitalograph | Brainomix | MannKind Corporation | Fortrea | Strados Labs | Ionis Pharmaceuticals, Inc. | IPS Therapeutique (IPST) Looking forward to reuniting the pulmonary fibrosis community once again to harness emerging biological understanding, apply novel and evolving models, and assess patient populations to propel innovative and efficacious therapeutics through phase 2 & beyond. Hope to see you with the pulmonary fibrosis community at the 8th IPF Summit! #ipfsummit #ipf2024 #pulmonaryfibrosis #fibrosis #IPF #ILD #progressivefibrosis #interstitiallungdisease #idiopathicpulmonaryfibrosis #lung #lungdisease #lunghealth #drugdevelopment #therapeuticdevelopment #conference #boston

For patients with newly diagnosed multiple myeloma (NDMM), the development of novel therapies and combinations in recent years has provided numerous therapeutic options. However, selecting optimal induction therapy and treatment sequencing remains a challenge. Join Dr. Gurbakhash Kaur, Assistant Professor of Internal Medicine at the University of Texas Southwestern Medical Center, for an expert discussion on treatment combination and sequencing strategies recommended by current guidelines, the mechanisms of action and efficacy of anti-CD38 monoclonal antibodies, the roles of measurable residual disease (MRD) assessment in treatment, monitoring and managing toxicities associated with novel therapies, and strategies for optimizing survivorship care. 🔗 Register now to stay updated with the latest in NDMM treatment: https://bit.ly/3yxlqim #MultipleMyeloma #MedicalEducation #HealthcareProfessionals

🌍 Today is World Health Day, a global observance dedicated to recognizing health as a fundamental human right, promoting equitable access to quality healthcare around the world, and advocating for investment in innovation and research. At NANOGAP, we stand in solidarity with this mission, committed to advancing innovative technologies that improve people's well-being and provide therapeutic solutions. Through our spin-off company, ARJUNA Therapeutics, we harness the power of metal molecules to open new therapeutic avenues, especially in the fight against incurable cancers. Arjuna's innovative therapeutic molecular clusters (TMCs) represent a paradigm shift in drug development, targeting critical vulnerabilities to fight diseases more effectively. 🔬 In parallel, NANOGAP is working on the development of a rapid diagnostic kit for pneumonia. In collaboration with a Technology Incubator consortium, we aim to revolutionize pneumonia diagnosis, ensuring timely and accurate detection to improve patient outcomes. On this World Health Day, let us reaffirm our commitment to advancing health innovation and fostering a world where everyone can access the care they need. Together we can build a healthier and more resilient future for all 💯

📢 Weekly Top 5 Must-Read News in Market Access Today | 18-24 November Highlights in Health Sciences! Welcome to 18-24 November of our weekly newsletter series, where we bring you the most critical updates in market access, healthcare, and pharmaceuticals! Each week, we’ll highlight the top 5 stories making waves in the industry. In this first edition, delve into the collaborative global efforts advancing mpox vaccine trials 🧬, the transformative power of targeted therapies for rare cancers 💊, and AstraZeneca's latest innovations in infectious disease, showcased at IDWeek 2024 🦠. We also explore the shift among Austrian youth towards modern nicotine alternatives and introduce CHEERS-AI, a groundbreaking framework evaluating AI's economic impact in healthcare. Stay informed on these pivotal developments with our weekly insights—and don't miss future issues to keep up with everything happening in health sciences! Explore the full articles through the links below: 1️⃣ EU Champions New Strategies to Battle Superbugs: https://lnkd.in/dXdA3wjA 2️⃣ NICE Approves Crovalimab for PNH Treatment, Enhancing Patient Options: https://lnkd.in/dRmGUZ-s 3️⃣ Medtronic Introduces Smart MDI System for Personalized Insulin Management: https://lnkd.in/d4MGDXce 4️⃣Anzupgo® Cream: A New Era in CHE Treatment: https://lnkd.in/dN2_zK43 5️⃣AbbVie Launches ELAHERE in Europe to Treat Resistant Ovarian Cancer: https://lnkd.in/dYmGiBtj #MarketAccess #Healthcare #Pharma #Innovation #AI #WeeklyHealthUpdates

#RareDisease is tricky, we need information from multiple sources to learn more. My colleague, Amanda Singleton, ScM, CGC, MPH, is participating on this virtual panel. Grab some coffee and listen in. GeneDx #GeneticTesting #WholeExomeSequencing

🎉 Happy New Year from the TTV-GUIDE team! As 2025 begins, we are excited to continue our journey toward advancing kidney transplantation care through groundbreaking research and innovation. Here's what you can look forward to this year: 📅 ERA Conference, Vienna, June 4, 2025 Meet us at the ERA Conference in Vienna this June! This event will also coincide with our next project meeting, offering an excellent platform to share insights, connect with peers, and showcase the progress of our project. 🧪 Trial Progression The TTV GUIDE TX clinical trial continues to advance, paving the way for personalized immunosuppression strategies that could revolutionize kidney transplantation outcomes. 📚 Publications and Results Stay tuned for key publications and new data that will provide deeper insights into the potential of TTV-guided immunosuppression and its impact on patients and healthcare systems. 📅 Upcoming Webinars We will host two webinars in February in collaboration with the European Kidney Patients Foundation (EKPF): February 18, 2 p.m. CET TTV-Guided Immunosuppression Exploring the Role of the Torque Teno Virus (TTV) as a Biomarker for Personalized Immunosuppressive Drug Therapy in Kidney Transplant Recipients February 20, 2 p.m. CET Ethical Dimensions in Clinical Trials Informed Consent, Therapeutic Misconception, and Ethical Challenges in Research Save the dates and join us for engaging discussions with our experts! Register via 👉🏼👉🏼 https://lnkd.in/dXzzdj6f 📌 Stay tuned for more updates as the year unfolds! #TTVGuide #KidneyTransplantation #ClinicalTrials #PersonalizedMedicine #HealthcareInnovation #WomenInScience #EthicsInResearch #ERA2025 #Webinar #SaveTheDate #Horizon2020 #EUprojects

🎉 New Year, New Solutions for MASLD Research! 🧬 As 2025 kicks off, it’s time to explore new cutting-edge tools that drive breakthroughs in metabolic research. We’re proud to offer our iPSC-derived MASLD disease model—a transformative platform for tackling Metabolic-Associated Steatotic Liver Disease (MASLD). Our in vitro MASLD model represents an optimized cell platform for drug discovery applications and a principal tool for elucidating the underlying mechanisms of the disease Why choose DefiniGEN’s MASLD model? ✅ Human-relevant: Derived from human iPSCs, offering unparalleled physiological relevance. ✅ Scalable and consistent: Suitable for high-throughput research as cells can be scaled to meet your needs. ✅ Reproducible data: Our MASLD model is derived from a single donor, ensuring that there is no donor variation. Learn more about how our MASLD disease model can support your research: https://lnkd.in/eKp3q-UJ #MASLD #iPSC #DrugDiscovery #LiverHealth #MetabolicResearch #DefiniGEN